Stocks
Renata Launches First Terbinafine Shipment to the UK
Renata PLC, a leading pharmaceutical manufacturer in the country, has successfully exported its initial consignment of Terbinafine tablets to the United Kingdom, marking a significant milestone in its export portfolio.
The company’s secretary, Md Jubayer Alam, announced that this shipment expands Renata’s export range to 17 distinct products within the UK market. “We have received an order of approximately 200,000 boxes, valued at £150,000,” he stated.
In local currency terms, this translates to an export value of over Tk2.23 crore.
In a disclosure to stock exchanges on Wednesday, June 19, Renata PLC detailed the dispatch of the first batch of Terbinafine 250 mg tablets to the UK, where the product will be marketed under the brand name Terbimax. The tablets are manufactured at Renata’s MHRA-approved facility in Rajendrapur, Gazipur, and will be distributed by Renata (UK) Limited.
Terbinafine, an allylamine antifungal, is commonly used to treat onychomycosis, a fungal infection of the toenails or fingernails caused by dermatophytes. The global market for Terbinafine was valued at $614 million in 2023. In Bangladesh, this medication is also available under the brand name Terbimax.
Md Jubayer Alam emphasized the strong demand for Terbinafine in the UK. “The market for these products is expanding rapidly. With our entry into this market, we anticipate significant benefits for the company,” he said.
Renata PLC entered the UK market in 2018 through its subsidiary, Renata (UK) Limited. Currently, several products are being commercialized in the UK, supported by agreements with five distribution partners. According to its annual report, Renata (UK) Limited generated a consolidated revenue of Tk7.71 crore in FY23.
One of the Listed companies, National Polymer Limited has recommended 10.50% Cash Dividend for the year ended June 30, 2024.
It has reported Consolidated EPS of Tk 2.27 paisa, and Consolidated NAV per share of Tk 30.63 for the year ended March 31, 2024.
The Annual General Meeting (AGM) of the company will be held on December 18, through the digital platform. The record date for this has been fixed at October 22.
The Company also discloses its financial reports for the second quarter, (April – June 24).
As per the company’s consolidated life revenue account for April to June 2024, the excess of total income over total expenses, including claims (surplus), stood at Tk 1,394.24 million. This marks a significant increase from the surplus of Tk 823.68 million during the same period in 2023.
For the first half of 2024, from January to June, the company reported a surplus of Tk 2,177.57 million, compared to Tk 1,290.39 million in the corresponding period of the previous year.
Additionally, the Life Insurance Fund balance as of June 30, 2024, reached Tk 55,188.62 million, showing a net increase of Tk 5,892.25 million from Tk 49,296.37 million on June 30, 2023.
One of the Listed companies, Beacon Pharmaceuticals PLC has recommended 20% Cash dividend and 10% Cash Dividend to Sponsor Shareholder and Directors for the year ended June 30, 2024.
It has reported EPS of Tk 2.26 paisa, and NAV per share of Tk. 26.37 for the year ended June 30, 2024.
The Annual General Meeting (AGM) of the company will be held on December 23, through the digital platform. The record date for this has been fixed at October 27.
The Bangladesh Securities and Exchange Commission (BSEC) has removed three audit firms from its panel for their failure to secure enlistment with the Financial Reporting Council (FRC), according to a notice issued today.
The firms—A Hoque & Company, FAMES & R, and SK Barua & Company Chartered Accountants—were delisted following the FRC’s request. In December last year, the FRC published a list of enlisted audit firms and subsequently, in February, requested the BSEC to remove any firms that were not included on that list.
BSEC regulations mandate that financial statements signed by auditors outside its approved panel will not be accepted. With the removal of these three firms, the total number of audit firms on the BSEC panel has been reduced from 48 to 45.
Sources from the FRC revealed that 15-20 audit firms failed to secure enlistment last year, and approximately 45 chartered accountants are currently under restrictions imposed by the Institute of Chartered Accountants.
Although the delisted firms can no longer audit issuer companies or listed securities, they are allowed to complete audit and assurance services that were initiated before their removal, the BSEC clarified.
